时间标签：数据日期 2026-11-03 · 生成时间 2026-11-03 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/31 – 2026/11/03 ｜ 情报发生日期 2026-11-03
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
摘要（PubMed 原文节选）
In recent years, significant progress has been made in developing targeted therapy for non-small cell lung cancer (NSCLC). However, these therapies are only applicable to specific NSCLC groups with corresponding gene mutations. Therefore, developing novel targeted therapies to benefit more patients remains an important task. Our prior work demonstrated that LKB1-mutant NSCLC cells are highly susceptible to cell death induced by glucose starvation. In this study, we investigated a novel combinational therapeutic strategy utilizing a sodium-glucose co-transporter-2 (SGLT2) inhibitor canagliflozin and a covalent KRASG12C inhibitor adagrasib, two clinically approved therapeutics, to selectively …
对本项目的价值
中等价值：属「营养感知—自噬—蛋白稳态轴」方向；干预策略与临床试验栏目可用作本项目文献库与综述素材。 ｜ 价值分 2.4/5（★★☆☆☆）
全文不可及原因
无 PMCID 且 OpenAlex / Unpaywall 未提供可下载 OA PDF
原文题录
- 中文题名：卡格列净联合阿达格拉西布治疗 LKB1-KRAS G12C 共突变 NSCLC
- 英文标题：Combination of canagliflozin and adagrasib as a novel targeted therapy for LKB1-KRASG12C co-mutated NSCLC.
- 期刊与标识：Cancer Lett · PMID 42967565 · DOI 10.1016/j.canlet.2026.218934 · EDAT 2026-11-01